X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs LUPIN LTD - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER LUPIN LTD PFIZER/
LUPIN LTD
 
P/E (TTM) x 24.2 16.6 145.8% View Chart
P/BV x 3.8 3.9 99.5% View Chart
Dividend Yield % 0.8 0.8 105.7%  

Financials

 PFIZER   LUPIN LTD
EQUITY SHARE DATA
    PFIZER
Mar-16
LUPIN LTD
Mar-16
PFIZER/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs2,7242,127 128.1%   
Low Rs1,6111,294 124.5%   
Sales per share (Unadj.) Rs440.9304.1 145.0%  
Earnings per share (Unadj.) Rs48.750.4 96.6%  
Cash flow per share (Unadj.) Rs75.860.7 124.9%  
Dividends per share (Unadj.) Rs15.007.50 200.0%  
Dividend yield (eoy) %0.70.4 157.8%  
Book value per share (Unadj.) Rs462.9243.8 189.9%  
Shares outstanding (eoy) m45.75450.58 10.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.95.6 87.4%   
Avg P/E ratio x44.533.9 131.1%  
P/CF ratio (eoy) x28.628.2 101.5%  
Price / Book Value ratio x4.77.0 66.7%  
Dividend payout %30.814.9 207.0%   
Avg Mkt Cap Rs m99,163770,740 12.9%   
No. of employees `0002.916.4 17.7%   
Total wages/salary Rs m2,75821,077 13.1%   
Avg. sales/employee Rs Th6,981.78,379.6 83.3%   
Avg. wages/employee Rs Th954.51,289.0 74.0%   
Avg. net profit/employee Rs Th771.11,388.7 55.5%   
INCOME DATA
Net Sales Rs m20,170137,016 14.7%  
Other income Rs m8571,877 45.7%   
Total revenues Rs m21,028138,893 15.1%   
Gross profit Rs m4,31037,535 11.5%  
Depreciation Rs m1,2394,635 26.7%   
Interest Rs m5446 1.2%   
Profit before tax Rs m3,92334,330 11.4%   
Minority Interest Rs m0-88 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m990-   
Tax Rs m1,79411,536 15.6%   
Profit after tax Rs m2,22822,707 9.8%  
Gross profit margin %21.427.4 78.0%  
Effective tax rate %45.733.6 136.1%   
Net profit margin %11.016.6 66.6%  
BALANCE SHEET DATA
Current assets Rs m16,29997,790 16.7%   
Current liabilities Rs m7,59453,872 14.1%   
Net working cap to sales %43.232.1 134.6%  
Current ratio x2.11.8 118.2%  
Inventory Days Days6585 77.1%  
Debtors Days Days26121 21.2%  
Net fixed assets Rs m8,62286,379 10.0%   
Share capital Rs m458901 50.8%   
"Free" reserves Rs m20,722105,735 19.6%   
Net worth Rs m21,180109,844 19.3%   
Long term debt Rs m2553,739 0.0%   
Total assets Rs m29,137224,378 13.0%  
Interest coverage x755.577.9 969.3%   
Debt to equity ratio x00.5 0.2%  
Sales to assets ratio x0.70.6 113.4%   
Return on assets %7.710.3 74.3%  
Return on equity %10.520.7 50.9%  
Return on capital %19.021.2 89.6%  
Exports to sales %0.149.1 0.1%   
Imports to sales %17.57.4 234.8%   
Exports (fob) Rs m1267,244 0.0%   
Imports (cif) Rs m3,52610,199 34.6%   
Fx inflow Rs m5271,405 0.1%   
Fx outflow Rs m14017,807 0.8%   
Net fx Rs m-8853,598 -0.2%   
CASH FLOW
From Operations Rs m3,436-3,690 -93.1%  
From Investments Rs m-6,991-69,434 10.1%  
From Financial Activity Rs m-61958,126 -1.1%  
Net Cashflow Rs m-4,174-14,998 27.8%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 63.9 0.2 31,950.0%  
Indian inst/Mut Fund % 7.5 11.3 66.4%  
FIIs % 4.9 31.9 15.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 10.1 234.7%  
Shareholders   85,207 98,259 86.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   PLETHICO PHARMA  BIOCON LTD  J.B.CHEMICALS  ALKEM LABORATORIES  DIVIS LABORATORIES  

Compare PFIZER With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Lupin: Key Products Drive US growth (Quarterly Results Update - Detailed)

Sep 12, 2016

Lupin has announced its 1QFY17results. Net sales have grown by 40% YoY and net profits have surged by 55.1% YoY. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Aug 18, 2017 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS